We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
from Section 2 - Cancer Symptom Mechanisms and Models: Clinical and Basic Science
Published online by Cambridge University Press: 05 August 2011
High-dose therapy (chemotherapy with or without radiotherapy) followed either by autologous or allogeneic hematopoietic stem cell transplantation (HSCT) has improved overall survival and disease-free survival for patients with various malignant and nonmalignant hematological disorders. However, this therapeutic benefit has come at the expense of significant morbidity and occasional mortality.
Research focused on the first 3–4 weeks after the administration of high-dose therapy and HSCT (the acute phase) shows that most patients report multiple physical, affective, and cognitive symptoms. Commonly reported physical symptoms during the acute phase include nausea, vomiting, diarrhea, decreased appetite, dry mouth, insomnia, weakness, and fatigue. Cognitive symptoms, such as delirium, decreased concentration, and memory problems, also are common during the acute phase of transplantation. Numerous studies have found that patients may continue to experience distressing symptoms, such as fatigue, pain, sleep disturbance, cognitive dysfunction, eye problems, dry mouth, taste changes, cough, shortness of breath, depression, anxiety, and sexual dysfunction, months or years after transplantation.
In this chapter we examine the spectrum of symptoms produced by high-dose therapy combined with HSCT, the mechanisms underlying symptom development, and potential intervention strategies that can be used to ameliorate this symptom burden. Although HSCT can overcome the hematopoietic toxicities of cytoreductive therapies and allow patients to receive higher doses, other toxicities of high-dose therapy and HSCT may place a significant burden on patients. HSCT presents a challenge for health care providers and patients to find a balance between potentially curative therapy and the symptom burden caused by the therapy.
To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.
